Table 2 Baseline patient characteristics according to RAS/BRAF mutational status

	*RAS/BRAF* wild		*RAS* mut		*BRAF* ^V600E mut		*BRAF* ^non-V600E mut
	(n =94)		(n =40)		(n =9)		(n =7)
	No	%	No	%	No	%	No	%
Age, years
Median	64		63		64		63
Range	28–85		35–79		33–73		48–74
Gender
Male	64	68.1	18	45	4	44.4	1	14.3
Female	30	31.9	22	55	5	55.6	6	85.7
ECOG PS
0	53	56.4	22	55	3	33.3	3	42.9
1	38	40.4	17	42.5	6	66.7	4	57.1
2	3	3.2	1	2.5	0	0	0	0
Histology ^a
Well	17	18.1	11	27.5	1	11.1	1	14.3
Moderate	62	66	23	57.5	6	66.7	5	71.4
Poor	11	11.7	5	12.5	1	11.1	1	14.3
Others	4	4.3	1	2.5	1	11.1	0	0
Primary tumour site ^b
Right-sided colon	13	13.8	11	27.5	4	44.4	4	57.1
Left-sided colon or rectum	81	86.2	29	72.5	5	55.6	3	42.9
Resection of primary tumour
	77	81.9	35	87.5	8	88.9	7	100
Time to metastases
Synchronous	50	53.2	20	50	4	44.4	1	14.3
Metachronous	44	46.8	20	50	5	55.6	6	85.7
Number of metastases
1	33	35.1	10	25	5	55.6	0	0
>1	61	64.9	30	75	4	44.4	7	100
Metastatic site
Liver	61	64.9	25	62.5	4	44.4	4	57.1
Lung	49	52.1	27	67.5	3	33.3	6	85.7
Peritoneum	20	21.3	9	22.5	3	33.3	2	28.6
Lymph node	37	39.4	11	27.5	1	11.1	5	71.4
Reason of discontinuation for each cytotoxic agent as prior treatment
Fluoropyrimidine
Failure	94	100	40	100	9	100	7	100
Intolerance	0	0	0	0	0	0	0	0
Oxaliplatin
Failure	83	88.3	38	95	9	100	5	71.4
Intolerance	11	11.7	2	5	0	0	2	28.6
Irinotecan
Failure	94	100	40	100	9	100	7	100
Intolerance	0	0	0	0	0	0	0	0
Prior Bevacizumab
	74	78.7	33	82.5	8	88.9	7	100
Anti-EGFR antibody treatment
Cetuximab	66	70.2	29	72.5	6	66.7	5	71.4
Panitumumab	28	29.8	11	27.5	3	33.3	2	28.6
Combine use of Irinotecan
Yes	69	73.4	35	87.5	8	88.9	4	57.1
No	25	26.6	5	12.5	1	11.1	3	42.9

Abbreviations: ECOG=Eastern Cooperative Oncology Group; FP=fluoropyrimidine; mut=mutant; poor=poorly differentiated; well=well differentiated; moderate, moderately differentiated; wild=wild-type.
Wild-type RAS/BRAF was defined as all wild-type sequence with RAS, BRAF^V600E, and BRAF^non-V600E.
^aDefined according to Japanese Classification (ref: JSCCR, Japanese Classification of Colorectal Carcinoma, 2nd English Ed).
^bRight-sided tumours were defined as those arising anywhere from the caecum to the transverse colon, and left-sided tumours were defined as those arising anywhere from the splenic flexure to the rectosigmoid junction.

Search